Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against

Paediatric Respiratory Reviews

Volumn 14, Issue 2, 2013, Pages 128-129

  Isaacs, David ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cost effectiveness; Indication creep; Quality adjusted life years

Indexed keywords

MOTAVIZUMAB; PALIVIZUMAB; VIRUS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FUNDING; HOSPITAL ADMISSION; HUMAN; INFANT; INFECTION RISK; INTENSIVE CARE UNIT; PREMATURITY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY CARE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT, PREMATURE, DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

HUMANS; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RESPIRATORY CARE UNITS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL VACCINES;

EID: 84878537310     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2012.12.006     Document Type: Article

References (11)

1. Szabo S.M., Gooch K.L., Korol E.E., Bradt P., Vo P., Levy A.R. Respiratory distress syndrome at birth is a risk factor for hospitalization for lower respiratory tract infections in infancy. Pediatr Infect Dis J 2012 Sep 17, [Epub ahead of print].
2. Carbonell-Estrany X., Simões E.A., Dagan R., et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a non-inferiority trial. Pediatrics 2010, 125:e35-e51.
3. Wang E.E.L., Tang N.K. Immunoglobulin for preventing respiratory syncytial virus infection. The Cochrane Database of Systematic Reviews 1999, (Issue 3). CD001725.
4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537. The IMpact-RSV Study Group.
5. Isaacs D., Fitzgerald D. A seasonal cost-effectiveness analysis: the last Noel?. BMJ 2002, 325:1426.
6. Singer P. Why we must ration health care. New York Times, July 15, 2009. (accessed Nov 11th, 2012). http://www.nytimes.com/2009/07/19/magazine/19healthcare-t.html.
7. Australian Government Department of Health and Ageing. The Australian Immunisation Handbook. 9th edition. Canberra, Australian Government Publishing, 2008. (accessed November 11th, 2012). http://www.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-home.
8. Teale A., Deshpande S., Burls A. Palivizumab and the importance of cost-effectiveness. BMJ 2009, 338:1474-1476.
9. Wang D., Bayliss S., Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011, 15:iii-iv. 1-124.
10. Isaacs D. Palivizumab. An example of indication creep. BMJ 2009, 339:b2724.
11. Fitzgerald D., Isaacs D., Tobin B. Palivizumab: a debate about public funding. J Paed Child Health 2012, 48:373-377.